Eli Lilly and Company (NYSE:LLY) Shares Sold by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 161,874 shares of the company’s stock after selling 3,784 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Eli Lilly and Company were worth $94,360,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Oak Harbor Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 20.0% in the 4th quarter. Oak Harbor Wealth Partners LLC now owns 1,866 shares of the company’s stock valued at $1,088,000 after purchasing an additional 311 shares in the last quarter. BlackDiamond Wealth Management LLC increased its holdings in Eli Lilly and Company by 5.1% in the fourth quarter. BlackDiamond Wealth Management LLC now owns 769 shares of the company’s stock valued at $448,000 after buying an additional 37 shares during the last quarter. Enterprise Financial Services Corp raised its stake in Eli Lilly and Company by 2.2% in the fourth quarter. Enterprise Financial Services Corp now owns 1,879 shares of the company’s stock valued at $1,095,000 after buying an additional 41 shares in the last quarter. Frazier Financial Advisors LLC purchased a new stake in Eli Lilly and Company during the 4th quarter worth about $239,000. Finally, Tidemark LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth about $29,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Bank of America boosted their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a report on Wednesday, February 21st. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price target (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday, April 30th. Finally, Wells Fargo & Company boosted their price target on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $769.53.

Eli Lilly and Company Price Performance

Shares of LLY traded up $4.85 on Thursday, hitting $807.76. The company’s stock had a trading volume of 1,754,312 shares, compared to its average volume of 2,992,665. Eli Lilly and Company has a fifty-two week low of $419.80 and a fifty-two week high of $820.61. The company has a market capitalization of $767.70 billion, a PE ratio of 119.61, a PEG ratio of 1.75 and a beta of 0.37. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The company has a 50 day moving average price of $763.51 and a 200 day moving average price of $690.03.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.62 earnings per share. On average, research analysts anticipate that Eli Lilly and Company will post 13.78 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Thursday, May 16th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend is Wednesday, May 15th. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.